open access

Vol 11, Supp. C (2015)
suplement
Published online: 2015-05-29
Get Citation

Abiraterone acetate — is only the second line palliative treatment?

Bartosz Itrych, Bożena Sikora-Kupis

open access

Vol 11, Supp. C (2015)
suplement
Published online: 2015-05-29

Abstract

One of the most common malignancies in men is prostate cancer [1]. The radical treatment of locally advanced prostate cancer are used such methods as surgery — radical prostatectomy and radiotherapy [2]. The use of hormonal therapy and palliative chemotherapy can extend the time to disease progression (PFS, progression-free survival) and overall survival (OS). Palliative hormonal therapy allows for regression biochemical improvement in general condition and reduce the pain caused by cancer. The use of anti-androgens, and steroids rotation, resulting in prolonged time to progression of the disease. In castration resistant prostate cancer to standard practice after failure of docetaxel, possible and only in Poland, is now the use of abiraterone acetate in the second line palliative treatment [3, 4].

The paper presents two cases of man with prostate cancer in the abiraterone acetate was used in the second and fifth lines of therapy with a good therapeutic effect.

Abstract

One of the most common malignancies in men is prostate cancer [1]. The radical treatment of locally advanced prostate cancer are used such methods as surgery — radical prostatectomy and radiotherapy [2]. The use of hormonal therapy and palliative chemotherapy can extend the time to disease progression (PFS, progression-free survival) and overall survival (OS). Palliative hormonal therapy allows for regression biochemical improvement in general condition and reduce the pain caused by cancer. The use of anti-androgens, and steroids rotation, resulting in prolonged time to progression of the disease. In castration resistant prostate cancer to standard practice after failure of docetaxel, possible and only in Poland, is now the use of abiraterone acetate in the second line palliative treatment [3, 4].

The paper presents two cases of man with prostate cancer in the abiraterone acetate was used in the second and fifth lines of therapy with a good therapeutic effect.

Get Citation

Keywords

prostate cancer, CRPC, castration resistance, abiraterone acetate

About this article
Title

Abiraterone acetate — is only the second line palliative treatment?

Journal

Oncology in Clinical Practice

Issue

Vol 11, Supp. C (2015)

Published online

2015-05-29

Keywords

prostate cancer
CRPC
castration resistance
abiraterone acetate

Authors

Bartosz Itrych
Bożena Sikora-Kupis

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl